COVID-19 Impact on Global Alpha- Antitrypsin Deficiency Treatment Market Size, Status and Forecast 2020-2026
This report focuses on the global Alpha- Antitrypsin Deficiency Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Alpha- Antitrypsin Deficiency Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
The key players covered in this study
- Adverum Biotechnologies, Inc.
- Alnylam Pharmaceuticals, Inc.
- Applied Genetic Technologies Corporation
- Arrowhead Pharmaceuticals, Inc.
- Carolus Therapeutics, Inc.
- Cevec Pharmaceuticals GmbH
- Dicerna Pharmaceuticals, Inc.
- Digna Biotech, S.L.
- Editas Medicine, Inc.
- Grifols, S.A.
- Inhibrx
- Intellia Therapeutics, Inc.
- International Stem Cell Corporation
- Ionis Pharmaceuticals, Inc.
- Kamada Ltd.
- Polyphor Ltd.
- ProMetic Life Sciences Inc.
- rEVO Biologics, Inc.
- Sangamo BioSciences, Inc.
- CT-2009
- POL-6014
- ARO-AAT
- ALNAAT-02
- Others
- Clinic
- Hospital
- Others
- North America
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America
- To analyze global Alpha- Antitrypsin Deficiency Treatment status, future forecast, growth opportunity, key market and key players.
- To present the Alpha- Antitrypsin Deficiency Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by type, market and key regions.
- History Year: 2015-2019
- Base Year: 2019
- Estimated Year: 2020
- Forecast Year 2020 to 2026
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Alpha- Antitrypsin Deficiency Treatment Revenue
1.4 Market Analysis by Type
1.4.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 CT-2009
1.4.3 POL-6014
1.4.4 ARO-AAT
1.4.5 ALNAAT-02
1.4.6 Others
1.5 Market by Application
1.5.1 Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application: 2020 VS 2026
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Alpha- Antitrypsin Deficiency Treatment Industry Impact
1.6.1 How the Covid-19 is Affecting the Alpha- Antitrypsin Deficiency Treatment Industry
1.6.1.1 Alpha- Antitrypsin Deficiency Treatment Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Alpha- Antitrypsin Deficiency Treatment Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Alpha- Antitrypsin Deficiency Treatment Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Alpha- Antitrypsin Deficiency Treatment Market Perspective (2015-2026)
2.2 Alpha- Antitrypsin Deficiency Treatment Growth Trends by Regions
2.2.1 Alpha- Antitrypsin Deficiency Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Alpha- Antitrypsin Deficiency Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Alpha- Antitrypsin Deficiency Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Alpha- Antitrypsin Deficiency Treatment Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Alpha- Antitrypsin Deficiency Treatment Players by Market Size
3.1.1 Global Top Alpha- Antitrypsin Deficiency Treatment Players by Revenue (2015-2020)
3.1.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio
3.2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Alpha- Antitrypsin Deficiency Treatment Revenue in 2019
3.3 Alpha- Antitrypsin Deficiency Treatment Key Players Head office and Area Served
3.4 Key Players Alpha- Antitrypsin Deficiency Treatment Product Solution and Service
3.5 Date of Enter into Alpha- Antitrypsin Deficiency Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Type (2015-2020)
4.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Type (2021-2026)
5 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
5.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
6.2 Alpha- Antitrypsin Deficiency Treatment Key Players in North America (2019-2020)
6.3 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
6.4 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
7.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Europe (2019-2020)
7.3 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
7.4 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
8 CHINA
8.1 China Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
8.2 Alpha- Antitrypsin Deficiency Treatment Key Players in China (2019-2020)
8.3 China Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
8.4 China Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
9.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Japan (2019-2020)
9.3 Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
9.4 Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
10.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
11 INDIA
11.1 India Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
11.2 Alpha- Antitrypsin Deficiency Treatment Key Players in India (2019-2020)
11.3 India Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
11.4 India Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
12.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
12.4 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Adverum Biotechnologies, Inc.
13.1.1 Adverum Biotechnologies, Inc. Company Details
13.1.2 Adverum Biotechnologies, Inc. Business Overview and Its Total Revenue
13.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.1.4 Adverum Biotechnologies, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020))
13.1.5 Adverum Biotechnologies, Inc. Recent Development
13.2 Alnylam Pharmaceuticals, Inc.
13.2.1 Alnylam Pharmaceuticals, Inc. Company Details
13.2.2 Alnylam Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.2.4 Alnylam Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.2.5 Alnylam Pharmaceuticals, Inc. Recent Development
13.3 Applied Genetic Technologies Corporation
13.3.1 Applied Genetic Technologies Corporation Company Details
13.3.2 Applied Genetic Technologies Corporation Business Overview and Its Total Revenue
13.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
13.3.4 Applied Genetic Technologies Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.3.5 Applied Genetic Technologies Corporation Recent Development
13.4 Arrowhead Pharmaceuticals, Inc.
13.4.1 Arrowhead Pharmaceuticals, Inc. Company Details
13.4.2 Arrowhead Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.4.4 Arrowhead Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.4.5 Arrowhead Pharmaceuticals, Inc. Recent Development
13.5 Carolus Therapeutics, Inc.
13.5.1 Carolus Therapeutics, Inc. Company Details
13.5.2 Carolus Therapeutics, Inc. Business Overview and Its Total Revenue
13.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.5.4 Carolus Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.5.5 Carolus Therapeutics, Inc. Recent Development
13.6 Cevec Pharmaceuticals GmbH
13.6.1 Cevec Pharmaceuticals GmbH Company Details
13.6.2 Cevec Pharmaceuticals GmbH Business Overview and Its Total Revenue
13.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Introduction
13.6.4 Cevec Pharmaceuticals GmbH Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.6.5 Cevec Pharmaceuticals GmbH Recent Development
13.7 Dicerna Pharmaceuticals, Inc.
13.7.1 Dicerna Pharmaceuticals, Inc. Company Details
13.7.2 Dicerna Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.7.4 Dicerna Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.7.5 Dicerna Pharmaceuticals, Inc. Recent Development
13.8 Digna Biotech, S.L.
13.8.1 Digna Biotech, S.L. Company Details
13.8.2 Digna Biotech, S.L. Business Overview and Its Total Revenue
13.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Introduction
13.8.4 Digna Biotech, S.L. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.8.5 Digna Biotech, S.L. Recent Development
13.9 Editas Medicine, Inc.
13.9.1 Editas Medicine, Inc. Company Details
13.9.2 Editas Medicine, Inc. Business Overview and Its Total Revenue
13.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.9.4 Editas Medicine, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.9.5 Editas Medicine, Inc. Recent Development
13.10 Grifols, S.A.
13.10.1 Grifols, S.A. Company Details
13.10.2 Grifols, S.A. Business Overview and Its Total Revenue
13.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Introduction
13.10.4 Grifols, S.A. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.10.5 Grifols, S.A. Recent Development
13.11 Inhibrx
10.11.1 Inhibrx Company Details
10.11.2 Inhibrx Business Overview and Its Total Revenue
10.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Introduction
10.11.4 Inhibrx Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.11.5 Inhibrx Recent Development
13.12 Intellia Therapeutics, Inc.
10.12.1 Intellia Therapeutics, Inc. Company Details
10.12.2 Intellia Therapeutics, Inc. Business Overview and Its Total Revenue
10.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.12.4 Intellia Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.12.5 Intellia Therapeutics, Inc. Recent Development
13.13 International Stem Cell Corporation
10.13.1 International Stem Cell Corporation Company Details
10.13.2 International Stem Cell Corporation Business Overview and Its Total Revenue
10.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
10.13.4 International Stem Cell Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.13.5 International Stem Cell Corporation Recent Development
13.14 Ionis Pharmaceuticals, Inc.
10.14.1 Ionis Pharmaceuticals, Inc. Company Details
10.14.2 Ionis Pharmaceuticals, Inc. Business Overview and Its Total Revenue
10.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.14.4 Ionis Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.14.5 Ionis Pharmaceuticals, Inc. Recent Development
13.15 Kamada Ltd.
10.15.1 Kamada Ltd. Company Details
10.15.2 Kamada Ltd. Business Overview and Its Total Revenue
10.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
10.15.4 Kamada Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.15.5 Kamada Ltd. Recent Development
13.16 Polyphor Ltd.
10.16.1 Polyphor Ltd. Company Details
10.16.2 Polyphor Ltd. Business Overview and Its Total Revenue
10.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
10.16.4 Polyphor Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.16.5 Polyphor Ltd. Recent Development
13.17 ProMetic Life Sciences Inc.
10.17.1 ProMetic Life Sciences Inc. Company Details
10.17.2 ProMetic Life Sciences Inc. Business Overview and Its Total Revenue
10.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.17.4 ProMetic Life Sciences Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.17.5 ProMetic Life Sciences Inc. Recent Development
13.18 rEVO Biologics, Inc.
10.18.1 rEVO Biologics, Inc. Company Details
10.18.2 rEVO Biologics, Inc. Business Overview and Its Total Revenue
10.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.18.4 rEVO Biologics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.18.5 rEVO Biologics, Inc. Recent Development
13.19 Sangamo BioSciences, Inc.
10.19.1 Sangamo BioSciences, Inc. Company Details
10.19.2 Sangamo BioSciences, Inc. Business Overview and Its Total Revenue
10.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.19.4 Sangamo BioSciences, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.19.5 Sangamo BioSciences, Inc. Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Alpha- Antitrypsin Deficiency Treatment Revenue
1.4 Market Analysis by Type
1.4.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 CT-2009
1.4.3 POL-6014
1.4.4 ARO-AAT
1.4.5 ALNAAT-02
1.4.6 Others
1.5 Market by Application
1.5.1 Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application: 2020 VS 2026
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Alpha- Antitrypsin Deficiency Treatment Industry Impact
1.6.1 How the Covid-19 is Affecting the Alpha- Antitrypsin Deficiency Treatment Industry
1.6.1.1 Alpha- Antitrypsin Deficiency Treatment Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Alpha- Antitrypsin Deficiency Treatment Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Alpha- Antitrypsin Deficiency Treatment Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Alpha- Antitrypsin Deficiency Treatment Market Perspective (2015-2026)
2.2 Alpha- Antitrypsin Deficiency Treatment Growth Trends by Regions
2.2.1 Alpha- Antitrypsin Deficiency Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Alpha- Antitrypsin Deficiency Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Alpha- Antitrypsin Deficiency Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Alpha- Antitrypsin Deficiency Treatment Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Alpha- Antitrypsin Deficiency Treatment Players by Market Size
3.1.1 Global Top Alpha- Antitrypsin Deficiency Treatment Players by Revenue (2015-2020)
3.1.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio
3.2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Alpha- Antitrypsin Deficiency Treatment Revenue in 2019
3.3 Alpha- Antitrypsin Deficiency Treatment Key Players Head office and Area Served
3.4 Key Players Alpha- Antitrypsin Deficiency Treatment Product Solution and Service
3.5 Date of Enter into Alpha- Antitrypsin Deficiency Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Type (2015-2020)
4.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Type (2021-2026)
5 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
5.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
6.2 Alpha- Antitrypsin Deficiency Treatment Key Players in North America (2019-2020)
6.3 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
6.4 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
7.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Europe (2019-2020)
7.3 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
7.4 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
8 CHINA
8.1 China Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
8.2 Alpha- Antitrypsin Deficiency Treatment Key Players in China (2019-2020)
8.3 China Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
8.4 China Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
9.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Japan (2019-2020)
9.3 Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
9.4 Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
10.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
11 INDIA
11.1 India Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
11.2 Alpha- Antitrypsin Deficiency Treatment Key Players in India (2019-2020)
11.3 India Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
11.4 India Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
12.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
12.4 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Adverum Biotechnologies, Inc.
13.1.1 Adverum Biotechnologies, Inc. Company Details
13.1.2 Adverum Biotechnologies, Inc. Business Overview and Its Total Revenue
13.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.1.4 Adverum Biotechnologies, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020))
13.1.5 Adverum Biotechnologies, Inc. Recent Development
13.2 Alnylam Pharmaceuticals, Inc.
13.2.1 Alnylam Pharmaceuticals, Inc. Company Details
13.2.2 Alnylam Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.2.4 Alnylam Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.2.5 Alnylam Pharmaceuticals, Inc. Recent Development
13.3 Applied Genetic Technologies Corporation
13.3.1 Applied Genetic Technologies Corporation Company Details
13.3.2 Applied Genetic Technologies Corporation Business Overview and Its Total Revenue
13.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
13.3.4 Applied Genetic Technologies Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.3.5 Applied Genetic Technologies Corporation Recent Development
13.4 Arrowhead Pharmaceuticals, Inc.
13.4.1 Arrowhead Pharmaceuticals, Inc. Company Details
13.4.2 Arrowhead Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.4.4 Arrowhead Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.4.5 Arrowhead Pharmaceuticals, Inc. Recent Development
13.5 Carolus Therapeutics, Inc.
13.5.1 Carolus Therapeutics, Inc. Company Details
13.5.2 Carolus Therapeutics, Inc. Business Overview and Its Total Revenue
13.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.5.4 Carolus Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.5.5 Carolus Therapeutics, Inc. Recent Development
13.6 Cevec Pharmaceuticals GmbH
13.6.1 Cevec Pharmaceuticals GmbH Company Details
13.6.2 Cevec Pharmaceuticals GmbH Business Overview and Its Total Revenue
13.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Introduction
13.6.4 Cevec Pharmaceuticals GmbH Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.6.5 Cevec Pharmaceuticals GmbH Recent Development
13.7 Dicerna Pharmaceuticals, Inc.
13.7.1 Dicerna Pharmaceuticals, Inc. Company Details
13.7.2 Dicerna Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.7.4 Dicerna Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.7.5 Dicerna Pharmaceuticals, Inc. Recent Development
13.8 Digna Biotech, S.L.
13.8.1 Digna Biotech, S.L. Company Details
13.8.2 Digna Biotech, S.L. Business Overview and Its Total Revenue
13.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Introduction
13.8.4 Digna Biotech, S.L. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.8.5 Digna Biotech, S.L. Recent Development
13.9 Editas Medicine, Inc.
13.9.1 Editas Medicine, Inc. Company Details
13.9.2 Editas Medicine, Inc. Business Overview and Its Total Revenue
13.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.9.4 Editas Medicine, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.9.5 Editas Medicine, Inc. Recent Development
13.10 Grifols, S.A.
13.10.1 Grifols, S.A. Company Details
13.10.2 Grifols, S.A. Business Overview and Its Total Revenue
13.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Introduction
13.10.4 Grifols, S.A. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.10.5 Grifols, S.A. Recent Development
13.11 Inhibrx
10.11.1 Inhibrx Company Details
10.11.2 Inhibrx Business Overview and Its Total Revenue
10.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Introduction
10.11.4 Inhibrx Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.11.5 Inhibrx Recent Development
13.12 Intellia Therapeutics, Inc.
10.12.1 Intellia Therapeutics, Inc. Company Details
10.12.2 Intellia Therapeutics, Inc. Business Overview and Its Total Revenue
10.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.12.4 Intellia Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.12.5 Intellia Therapeutics, Inc. Recent Development
13.13 International Stem Cell Corporation
10.13.1 International Stem Cell Corporation Company Details
10.13.2 International Stem Cell Corporation Business Overview and Its Total Revenue
10.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
10.13.4 International Stem Cell Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.13.5 International Stem Cell Corporation Recent Development
13.14 Ionis Pharmaceuticals, Inc.
10.14.1 Ionis Pharmaceuticals, Inc. Company Details
10.14.2 Ionis Pharmaceuticals, Inc. Business Overview and Its Total Revenue
10.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.14.4 Ionis Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.14.5 Ionis Pharmaceuticals, Inc. Recent Development
13.15 Kamada Ltd.
10.15.1 Kamada Ltd. Company Details
10.15.2 Kamada Ltd. Business Overview and Its Total Revenue
10.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
10.15.4 Kamada Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.15.5 Kamada Ltd. Recent Development
13.16 Polyphor Ltd.
10.16.1 Polyphor Ltd. Company Details
10.16.2 Polyphor Ltd. Business Overview and Its Total Revenue
10.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
10.16.4 Polyphor Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.16.5 Polyphor Ltd. Recent Development
13.17 ProMetic Life Sciences Inc.
10.17.1 ProMetic Life Sciences Inc. Company Details
10.17.2 ProMetic Life Sciences Inc. Business Overview and Its Total Revenue
10.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.17.4 ProMetic Life Sciences Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.17.5 ProMetic Life Sciences Inc. Recent Development
13.18 rEVO Biologics, Inc.
10.18.1 rEVO Biologics, Inc. Company Details
10.18.2 rEVO Biologics, Inc. Business Overview and Its Total Revenue
10.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.18.4 rEVO Biologics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.18.5 rEVO Biologics, Inc. Recent Development
13.19 Sangamo BioSciences, Inc.
10.19.1 Sangamo BioSciences, Inc. Company Details
10.19.2 Sangamo BioSciences, Inc. Business Overview and Its Total Revenue
10.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.19.4 Sangamo BioSciences, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.19.5 Sangamo BioSciences, Inc. Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. Alpha- Antitrypsin Deficiency Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Alpha- Antitrypsin Deficiency Treatment Revenue
Table 3. Ranking of Global Top Alpha- Antitrypsin Deficiency Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of CT-2009
Table 6. Key Players of POL-6014
Table 7. Key Players of ARO-AAT
Table 8. Key Players of ALNAAT-02
Table 9. Key Players of Others
Table 10. COVID-19 Impact Global Market: (Four Alpha- Antitrypsin Deficiency Treatment Market Size Forecast Scenarios)
Table 11. Opportunities and Trends for Alpha- Antitrypsin Deficiency Treatment Players in the COVID-19 Landscape
Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 13. Key Regions/Countries Measures against Covid-19 Impact
Table 14. Proposal for Alpha- Antitrypsin Deficiency Treatment Players to Combat Covid-19 Impact
Table 15. Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions (2015-2020)
Table 19. Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Alpha- Antitrypsin Deficiency Treatment Market Growth Strategy
Table 25. Main Points Interviewed from Key Alpha- Antitrypsin Deficiency Treatment Players
Table 26. Global Alpha- Antitrypsin Deficiency Treatment Revenue by Players (2015-2020) (Million US$)
Table 27. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Players (2015-2020)
Table 28. Global Top Alpha- Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2019)
Table 29. Global Alpha- Antitrypsin Deficiency Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Alpha- Antitrypsin Deficiency Treatment Product Solution and Service
Table 32. Date of Enter into Alpha- Antitrypsin Deficiency Treatment Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 35. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Type (2015-2020)
Table 36. Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Type (2021-2026)
Table 37. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Application (2015-2020)
Table 38. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 39. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Application (2021-2026)
Table 40. North America Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 42. North America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 43. North America Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 44. North America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 45. North America Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 46. Europe Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 48. Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 50. Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 52. China Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 53. China Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 54. China Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 55. China Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 56. China Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 57. China Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 58. Japan Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 60. Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 62. Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 66. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 68. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 70. India Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 71. India Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 72. India Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 73. India Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 74. India Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 75. India Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 78. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 80. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 82. Adverum Biotechnologies, Inc. Company Details
Table 83. Adverum Biotechnologies, Inc. Business Overview
Table 84. Adverum Biotechnologies, Inc. Product
Table 85. Adverum Biotechnologies, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 86. Adverum Biotechnologies, Inc. Recent Development
Table 87. Alnylam Pharmaceuticals, Inc. Company Details
Table 88. Alnylam Pharmaceuticals, Inc. Business Overview
Table 89. Alnylam Pharmaceuticals, Inc. Product
Table 90. Alnylam Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 91. Alnylam Pharmaceuticals, Inc. Recent Development
Table 92. Applied Genetic Technologies Corporation Company Details
Table 93. Applied Genetic Technologies Corporation Business Overview
Table 94. Applied Genetic Technologies Corporation Product
Table 95. Applied Genetic Technologies Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 96. Applied Genetic Technologies Corporation Recent Development
Table 97. Arrowhead Pharmaceuticals, Inc. Company Details
Table 98. Arrowhead Pharmaceuticals, Inc. Business Overview
Table 99. Arrowhead Pharmaceuticals, Inc. Product
Table 100. Arrowhead Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 101. Arrowhead Pharmaceuticals, Inc. Recent Development
Table 102. Carolus Therapeutics, Inc. Company Details
Table 103. Carolus Therapeutics, Inc. Business Overview
Table 104. Carolus Therapeutics, Inc. Product
Table 105. Carolus Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 106. Carolus Therapeutics, Inc. Recent Development
Table 107. Cevec Pharmaceuticals GmbH Company Details
Table 108. Cevec Pharmaceuticals GmbH Business Overview
Table 109. Cevec Pharmaceuticals GmbH Product
Table 110. Cevec Pharmaceuticals GmbH Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 111. Cevec Pharmaceuticals GmbH Recent Development
Table 112. Dicerna Pharmaceuticals, Inc. Company Details
Table 113. Dicerna Pharmaceuticals, Inc. Business Overview
Table 114. Dicerna Pharmaceuticals, Inc. Product
Table 115. Dicerna Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 116. Dicerna Pharmaceuticals, Inc. Recent Development
Table 117. Digna Biotech, S.L. Business Overview
Table 118. Digna Biotech, S.L. Product
Table 119. Digna Biotech, S.L. Company Details
Table 120. Digna Biotech, S.L. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 121. Digna Biotech, S.L. Recent Development
Table 122. Editas Medicine, Inc. Company Details
Table 123. Editas Medicine, Inc. Business Overview
Table 124. Editas Medicine, Inc. Product
Table 125. Editas Medicine, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 126. Editas Medicine, Inc. Recent Development
Table 127. Grifols, S.A. Company Details
Table 128. Grifols, S.A. Business Overview
Table 129. Grifols, S.A. Product
Table 130. Grifols, S.A. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 131. Grifols, S.A. Recent Development
Table 132. Inhibrx Company Details
Table 133. Inhibrx Business Overview
Table 134. Inhibrx Product
Table 135. Inhibrx Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 136. Inhibrx Recent Development
Table 137. Intellia Therapeutics, Inc. Company Details
Table 138. Intellia Therapeutics, Inc. Business Overview
Table 139. Intellia Therapeutics, Inc. Product
Table 140. Intellia Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 141. Intellia Therapeutics, Inc. Recent Development
Table 142. International Stem Cell Corporation Company Details
Table 143. International Stem Cell Corporation Business Overview
Table 144. International Stem Cell Corporation Product
Table 145. International Stem Cell Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 146. International Stem Cell Corporation Recent Development
Table 147. Ionis Pharmaceuticals, Inc. Company Details
Table 148. Ionis Pharmaceuticals, Inc. Business Overview
Table 149. Ionis Pharmaceuticals, Inc. Product
Table 150. Ionis Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 151. Ionis Pharmaceuticals, Inc. Recent Development
Table 152. Kamada Ltd. Company Details
Table 153. Kamada Ltd. Business Overview
Table 154. Kamada Ltd. Product
Table 155. Kamada Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 156. Kamada Ltd. Recent Development
Table 157. Polyphor Ltd. Company Details
Table 158. Polyphor Ltd. Business Overview
Table 159. Polyphor Ltd. Product
Table 160. Polyphor Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 161. Polyphor Ltd. Recent Development
Table 162. ProMetic Life Sciences Inc. Company Details
Table 163. ProMetic Life Sciences Inc. Business Overview
Table 164. ProMetic Life Sciences Inc. Product
Table 165. ProMetic Life Sciences Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 166. ProMetic Life Sciences Inc. Recent Development
Table 167. rEVO Biologics, Inc. Company Details
Table 168. rEVO Biologics, Inc. Business Overview
Table 169. rEVO Biologics, Inc. Product
Table 170. rEVO Biologics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 171. rEVO Biologics, Inc. Recent Development
Table 172. Sangamo BioSciences, Inc. Company Details
Table 173. Sangamo BioSciences, Inc. Business Overview
Table 174. Sangamo BioSciences, Inc. Product
Table 175. Sangamo BioSciences, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 176. Sangamo BioSciences, Inc. Recent Development
Table 177. Research Programs/Design for This Report
Table 178. Key Data Information from Secondary Sources
Table 179. Key Data Information from Primary Sources
Table 1. Alpha- Antitrypsin Deficiency Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Alpha- Antitrypsin Deficiency Treatment Revenue
Table 3. Ranking of Global Top Alpha- Antitrypsin Deficiency Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of CT-2009
Table 6. Key Players of POL-6014
Table 7. Key Players of ARO-AAT
Table 8. Key Players of ALNAAT-02
Table 9. Key Players of Others
Table 10. COVID-19 Impact Global Market: (Four Alpha- Antitrypsin Deficiency Treatment Market Size Forecast Scenarios)
Table 11. Opportunities and Trends for Alpha- Antitrypsin Deficiency Treatment Players in the COVID-19 Landscape
Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 13. Key Regions/Countries Measures against Covid-19 Impact
Table 14. Proposal for Alpha- Antitrypsin Deficiency Treatment Players to Combat Covid-19 Impact
Table 15. Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions (2015-2020)
Table 19. Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Alpha- Antitrypsin Deficiency Treatment Market Growth Strategy
Table 25. Main Points Interviewed from Key Alpha- Antitrypsin Deficiency Treatment Players
Table 26. Global Alpha- Antitrypsin Deficiency Treatment Revenue by Players (2015-2020) (Million US$)
Table 27. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Players (2015-2020)
Table 28. Global Top Alpha- Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2019)
Table 29. Global Alpha- Antitrypsin Deficiency Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Alpha- Antitrypsin Deficiency Treatment Product Solution and Service
Table 32. Date of Enter into Alpha- Antitrypsin Deficiency Treatment Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 35. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Type (2015-2020)
Table 36. Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Type (2021-2026)
Table 37. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Application (2015-2020)
Table 38. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 39. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Application (2021-2026)
Table 40. North America Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 42. North America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 43. North America Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 44. North America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 45. North America Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 46. Europe Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 48. Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 50. Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 52. China Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 53. China Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 54. China Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 55. China Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 56. China Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 57. China Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 58. Japan Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 60. Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 62. Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 66. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 68. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 70. India Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 71. India Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 72. India Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 73. India Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 74. India Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 75. India Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 78. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 80. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 82. Adverum Biotechnologies, Inc. Company Details
Table 83. Adverum Biotechnologies, Inc. Business Overview
Table 84. Adverum Biotechnologies, Inc. Product
Table 85. Adverum Biotechnologies, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 86. Adverum Biotechnologies, Inc. Recent Development
Table 87. Alnylam Pharmaceuticals, Inc. Company Details
Table 88. Alnylam Pharmaceuticals, Inc. Business Overview
Table 89. Alnylam Pharmaceuticals, Inc. Product
Table 90. Alnylam Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 91. Alnylam Pharmaceuticals, Inc. Recent Development
Table 92. Applied Genetic Technologies Corporation Company Details
Table 93. Applied Genetic Technologies Corporation Business Overview
Table 94. Applied Genetic Technologies Corporation Product
Table 95. Applied Genetic Technologies Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 96. Applied Genetic Technologies Corporation Recent Development
Table 97. Arrowhead Pharmaceuticals, Inc. Company Details
Table 98. Arrowhead Pharmaceuticals, Inc. Business Overview
Table 99. Arrowhead Pharmaceuticals, Inc. Product
Table 100. Arrowhead Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 101. Arrowhead Pharmaceuticals, Inc. Recent Development
Table 102. Carolus Therapeutics, Inc. Company Details
Table 103. Carolus Therapeutics, Inc. Business Overview
Table 104. Carolus Therapeutics, Inc. Product
Table 105. Carolus Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 106. Carolus Therapeutics, Inc. Recent Development
Table 107. Cevec Pharmaceuticals GmbH Company Details
Table 108. Cevec Pharmaceuticals GmbH Business Overview
Table 109. Cevec Pharmaceuticals GmbH Product
Table 110. Cevec Pharmaceuticals GmbH Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 111. Cevec Pharmaceuticals GmbH Recent Development
Table 112. Dicerna Pharmaceuticals, Inc. Company Details
Table 113. Dicerna Pharmaceuticals, Inc. Business Overview
Table 114. Dicerna Pharmaceuticals, Inc. Product
Table 115. Dicerna Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 116. Dicerna Pharmaceuticals, Inc. Recent Development
Table 117. Digna Biotech, S.L. Business Overview
Table 118. Digna Biotech, S.L. Product
Table 119. Digna Biotech, S.L. Company Details
Table 120. Digna Biotech, S.L. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 121. Digna Biotech, S.L. Recent Development
Table 122. Editas Medicine, Inc. Company Details
Table 123. Editas Medicine, Inc. Business Overview
Table 124. Editas Medicine, Inc. Product
Table 125. Editas Medicine, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 126. Editas Medicine, Inc. Recent Development
Table 127. Grifols, S.A. Company Details
Table 128. Grifols, S.A. Business Overview
Table 129. Grifols, S.A. Product
Table 130. Grifols, S.A. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 131. Grifols, S.A. Recent Development
Table 132. Inhibrx Company Details
Table 133. Inhibrx Business Overview
Table 134. Inhibrx Product
Table 135. Inhibrx Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 136. Inhibrx Recent Development
Table 137. Intellia Therapeutics, Inc. Company Details
Table 138. Intellia Therapeutics, Inc. Business Overview
Table 139. Intellia Therapeutics, Inc. Product
Table 140. Intellia Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 141. Intellia Therapeutics, Inc. Recent Development
Table 142. International Stem Cell Corporation Company Details
Table 143. International Stem Cell Corporation Business Overview
Table 144. International Stem Cell Corporation Product
Table 145. International Stem Cell Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 146. International Stem Cell Corporation Recent Development
Table 147. Ionis Pharmaceuticals, Inc. Company Details
Table 148. Ionis Pharmaceuticals, Inc. Business Overview
Table 149. Ionis Pharmaceuticals, Inc. Product
Table 150. Ionis Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 151. Ionis Pharmaceuticals, Inc. Recent Development
Table 152. Kamada Ltd. Company Details
Table 153. Kamada Ltd. Business Overview
Table 154. Kamada Ltd. Product
Table 155. Kamada Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 156. Kamada Ltd. Recent Development
Table 157. Polyphor Ltd. Company Details
Table 158. Polyphor Ltd. Business Overview
Table 159. Polyphor Ltd. Product
Table 160. Polyphor Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 161. Polyphor Ltd. Recent Development
Table 162. ProMetic Life Sciences Inc. Company Details
Table 163. ProMetic Life Sciences Inc. Business Overview
Table 164. ProMetic Life Sciences Inc. Product
Table 165. ProMetic Life Sciences Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 166. ProMetic Life Sciences Inc. Recent Development
Table 167. rEVO Biologics, Inc. Company Details
Table 168. rEVO Biologics, Inc. Business Overview
Table 169. rEVO Biologics, Inc. Product
Table 170. rEVO Biologics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 171. rEVO Biologics, Inc. Recent Development
Table 172. Sangamo BioSciences, Inc. Company Details
Table 173. Sangamo BioSciences, Inc. Business Overview
Table 174. Sangamo BioSciences, Inc. Product
Table 175. Sangamo BioSciences, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 176. Sangamo BioSciences, Inc. Recent Development
Table 177. Research Programs/Design for This Report
Table 178. Key Data Information from Secondary Sources
Table 179. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Type: 2020 VS 2026
Figure 2. CT-2009 Features
Figure 3. POL-6014 Features
Figure 4. ARO-AAT Features
Figure 5. ALNAAT-02 Features
Figure 6. Others Features
Figure 7. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application: 2020 VS 2026
Figure 8. Clinic Case Studies
Figure 9. Hospital Case Studies
Figure 10. Others Case Studies
Figure 11. Alpha- Antitrypsin Deficiency Treatment Report Years Considered
Figure 12. Global Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions: 2020 VS 2026
Figure 14. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Players in 2019
Figure 17. Global Top Alpha- Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Alpha- Antitrypsin Deficiency Treatment Revenue in 2019
Figure 19. North America Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Adverum Biotechnologies, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Adverum Biotechnologies, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 28. Alnylam Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Alnylam Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 30. Applied Genetic Technologies Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Applied Genetic Technologies Corporation Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 32. Arrowhead Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Arrowhead Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 34. Carolus Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Carolus Therapeutics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 36. Cevec Pharmaceuticals GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Cevec Pharmaceuticals GmbH Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 38. Dicerna Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Dicerna Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 40. Digna Biotech, S.L. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Digna Biotech, S.L. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 42. Editas Medicine, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Editas Medicine, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 44. Grifols, S.A. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Grifols, S.A. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 46. Inhibrx Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Inhibrx Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 48. Intellia Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Intellia Therapeutics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 50. International Stem Cell Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. International Stem Cell Corporation Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 52. Ionis Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Ionis Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 54. Kamada Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Kamada Ltd. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 56. Polyphor Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Polyphor Ltd. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 58. ProMetic Life Sciences Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. ProMetic Life Sciences Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 60. rEVO Biologics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. rEVO Biologics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 62. Sangamo BioSciences, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Sangamo BioSciences, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Figure 1. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Type: 2020 VS 2026
Figure 2. CT-2009 Features
Figure 3. POL-6014 Features
Figure 4. ARO-AAT Features
Figure 5. ALNAAT-02 Features
Figure 6. Others Features
Figure 7. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application: 2020 VS 2026
Figure 8. Clinic Case Studies
Figure 9. Hospital Case Studies
Figure 10. Others Case Studies
Figure 11. Alpha- Antitrypsin Deficiency Treatment Report Years Considered
Figure 12. Global Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions: 2020 VS 2026
Figure 14. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Players in 2019
Figure 17. Global Top Alpha- Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Alpha- Antitrypsin Deficiency Treatment Revenue in 2019
Figure 19. North America Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Adverum Biotechnologies, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Adverum Biotechnologies, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 28. Alnylam Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Alnylam Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 30. Applied Genetic Technologies Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Applied Genetic Technologies Corporation Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 32. Arrowhead Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Arrowhead Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 34. Carolus Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Carolus Therapeutics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 36. Cevec Pharmaceuticals GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Cevec Pharmaceuticals GmbH Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 38. Dicerna Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Dicerna Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 40. Digna Biotech, S.L. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Digna Biotech, S.L. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 42. Editas Medicine, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Editas Medicine, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 44. Grifols, S.A. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Grifols, S.A. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 46. Inhibrx Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Inhibrx Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 48. Intellia Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Intellia Therapeutics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 50. International Stem Cell Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. International Stem Cell Corporation Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 52. Ionis Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Ionis Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 54. Kamada Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Kamada Ltd. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 56. Polyphor Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Polyphor Ltd. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 58. ProMetic Life Sciences Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. ProMetic Life Sciences Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 60. rEVO Biologics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. rEVO Biologics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 62. Sangamo BioSciences, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Sangamo BioSciences, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
